IVA · NASDAQ
Inventiva S.A.
$3.83 -0.08 (-2.14%)
Company overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed a Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed a Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier-stage programs in oncology and other diseases. The company has strategic collaborations with AbbVie for the treatment of autoimmune diseases and with Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $199M
- Employees
- 114
- Headquarters
- Daix
- Website
- inventivapharma.com
- CEO
- Andrew Obenshain
- Listed
- July 10, 2020
- P/E
- -0.70
- Dividend yield
- 0.00%
Company financials
- Revenue
- $13.7M
- Gross profit
- $10.8M
- Operating income
- -$229M
- EBITDA
- -$410M
- Net income
- -$537M
- EPS
- -$5.44
- Total assets
- $249M
- Total debt
- $59.4M
- Gross margin
- 78.79%
- Net margin
- -3,925.44%
- Earnings yield
- -142.04%
No product segmentation.
Showing FY 2025
IVA
1D
NASDAQ
O3.62H3.99L3.56C3.84+0.19 (+5.21%)Vol2.08M
News